TOFACITINIB IMPROVES DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ACTIVE PSORIATIC ARTHRITIS (PSA) IN REAL CLINICAL PRACTICE.

被引：1
|
作者：
Korotaeva, T. [1 ]
Vorobyova, L. [1 ]
Loginova, E. [1 ]
Gubar, E. [1 ]
Korsakova, Y. [1 ]
Glukhova, S. [1 ]
Karpova, P. [1 ]
机构：
[1] Nasonova Res Inst Rheumatol, Moscow, Russia
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.2620
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0845
引用
收藏
页码：1725 / 1725
页数：1
相关论文
共 50 条
  • [31] Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
    Gossec, Laure
    Mease, Philip
    Gottlieb, Alice
    Assudani, Deepak
    Coarse, Jason
    Ink, Barbara
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [32] Disease Activity Assessment and Patient-Reported Outcomes in Patients with Early Rheumatoid Arthritis
    Sokka, Tuulikki
    Rannio, Tuomas
    Khan, Nasim A.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2012, 38 (02) : 299 - +
  • [33] The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
    Strand, Vibeke
    Kaeley, Gurjit S.
    Bergman, Martin J.
    Gladman, Dafna D.
    Coates, Laura C.
    Sherif, Bintu
    Hur, Peter
    Parikh, Bhumik
    Gilloteau, Isabelle
    Mease, Philip J.
    LANCET RHEUMATOLOGY, 2022, 4 (03): : E208 - E219
  • [34] IXEKIZUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS
    Kavanaugh, A.
    Vender, R.
    Birt, J.
    Adams, D. H.
    Benichou, O.
    Lin, C. -Y.
    Nash, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 941 - 941
  • [35] Psoriatic arthritis in Jordan: a cross-sectional study of disease characteristics, patient-reported outcomes, and disease activity
    Fatima Alnaimat
    Khaldoon Alawneh
    Ayman AbuHelal
    Omar Hamdan
    Almothana Alelaimat
    Manal Al Mashaleh
    Ausaylah Burqan
    Wala Rababah
    Rabaa Rababah
    Marwan Adwan
    BMC Rheumatology, 9 (1)
  • [36] Correlation of patient-reported routine assessment of patient index data with clinical measures of disease activity in psoriatic arthritis
    Ward, Louise
    Oliffe, Michael
    Kane, Barry
    Chessman, Diana
    Meaney, Donna
    Briggs, Fiona
    Gibson, Kathryn
    Barnsley, Les
    Sumpton, Daniel
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2022, 25 (05) : 584 - 591
  • [37] Sustained improvements in patient-reported outcomes in psoriatic arthritis patients treated with etanercept
    Mease, P
    Gottlieb, A
    Woolley, JM
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P2 - P2
  • [38] Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer.
    Patel, Shiven B.
    Haaland, Ben
    Ose, Dominik
    Haydell, Tyler
    Martineau, Jim
    Dunson, William A.
    Chalmers, Anna Weinberg
    Cannon, Laura
    Kissell, Betsy
    Meropol, Neal J.
    Akerley, Wallace L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Critical importance of patient-reported outcomes for a comprehensive assessment of psoriatic arthritis patients
    Lo Monaco, Marika
    Bocchio, Raffaella Mallaci
    Natoli, Giuseppe
    Giardina, Annarita
    Cangemi, Ignazio
    Scibetta, Salvatore
    Argano, Christiano
    Corrao, Salvatore
    FRONTIERS IN MEDICINE, 2024, 10
  • [40] Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2
    Vibeke Strand
    Filip Van den Bosch
    Roberto Ranza
    Ying-Ying Leung
    Edit Drescher
    Patrick Zueger
    Christopher D. Saffore
    Apinya Lertratanakul
    Ralph Lippe
    Peter Nash
    Rheumatology and Therapy, 2021, 8 : 1827 - 1844
12345